Jean‐Philippe Guégan

2.2k total citations
40 papers, 822 citations indexed

About

Jean‐Philippe Guégan is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jean‐Philippe Guégan has authored 40 papers receiving a total of 822 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 14 papers in Molecular Biology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jean‐Philippe Guégan's work include Cancer Immunotherapy and Biomarkers (17 papers), Lung Cancer Research Studies (5 papers) and Melanoma and MAPK Pathways (4 papers). Jean‐Philippe Guégan is often cited by papers focused on Cancer Immunotherapy and Biomarkers (17 papers), Lung Cancer Research Studies (5 papers) and Melanoma and MAPK Pathways (4 papers). Jean‐Philippe Guégan collaborates with scholars based in France, United States and Canada. Jean‐Philippe Guégan's co-authors include Antoîne Italiano, Alban Bessede, Patrick Legembre, Sophie Cousin, Georges Baffet, Christophe Frémin, Florent Peyraud, François Le Loarer, Frédéric Ezan and Sophie Langouët and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Oncogene.

In The Last Decade

Jean‐Philippe Guégan

38 papers receiving 816 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jean‐Philippe Guégan France 17 399 320 263 118 117 40 822
Yurong Zhang China 11 199 0.5× 413 1.3× 135 0.5× 91 0.8× 153 1.3× 32 656
Arif Y. Shaikh United States 9 291 0.7× 272 0.8× 223 0.8× 115 1.0× 145 1.2× 15 688
Yibing Bai China 12 378 0.9× 386 1.2× 301 1.1× 82 0.7× 152 1.3× 22 926
Lu Yue China 17 227 0.6× 627 2.0× 71 0.3× 119 1.0× 234 2.0× 34 866
Daya Luo China 15 225 0.6× 513 1.6× 137 0.5× 112 0.9× 318 2.7× 48 907
Carole Ferraro‐Peyret France 13 113 0.3× 300 0.9× 118 0.4× 59 0.5× 86 0.7× 28 673
Luyun He China 14 228 0.6× 724 2.3× 125 0.5× 100 0.8× 433 3.7× 24 1.0k
Jen‐Yu Hung Taiwan 18 439 1.1× 788 2.5× 276 1.0× 363 3.1× 570 4.9× 46 1.4k
Sara Baglivo Italy 17 661 1.7× 306 1.0× 109 0.4× 541 4.6× 187 1.6× 39 993
Rohit R. Jadhav United States 19 342 0.9× 439 1.4× 544 2.1× 138 1.2× 252 2.2× 30 1.2k

Countries citing papers authored by Jean‐Philippe Guégan

Since Specialization
Citations

This map shows the geographic impact of Jean‐Philippe Guégan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean‐Philippe Guégan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean‐Philippe Guégan more than expected).

Fields of papers citing papers by Jean‐Philippe Guégan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean‐Philippe Guégan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean‐Philippe Guégan. The network helps show where Jean‐Philippe Guégan may publish in the future.

Co-authorship network of co-authors of Jean‐Philippe Guégan

This figure shows the co-authorship network connecting the top 25 collaborators of Jean‐Philippe Guégan. A scholar is included among the top collaborators of Jean‐Philippe Guégan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean‐Philippe Guégan. Jean‐Philippe Guégan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Léonard, Simon, Fanélie Jouenne, Claire Drullion, et al.. (2025). Immune control of functional memory CD8 T cells in normal-appearing vitiligo skin. Science Advances. 11(50). eadu9360–eadu9360.
2.
Peyraud, Florent, Jean‐Philippe Guégan, Jean‐Yves Blay, et al.. (2025). 2687MO CONgRAtS: A randomized phase II study of nivolumab±relatlimab in patients with TLS-positive soft-tissue sarcomas. Annals of Oncology. 36. S1338–S1339.
3.
Peyraud, Florent, Jean‐Philippe Guégan, Lucile Vanhersecke, et al.. (2025). Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside. Med. 6(1). 100546–100546. 13 indexed citations
4.
Bellera, Carine, Jean‐Philippe Guégan, Julien Hadoux, et al.. (2024). 1925MO Regomune study: A phase II study of regorafenib + avelumab in solid tumors. Results of the radioiodine-refractory differentiated thyroid cancer (RR-DTC). Annals of Oncology. 35. S1120–S1120. 1 indexed citations
5.
Italiano, Antoîne, Jean‐Philippe Guégan, Thibaud Valentin, et al.. (2024). Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-VEGFR targeted therapy: A Phase 2 Trial of Regorafenib combined with avelumab.. Journal of Clinical Oncology. 42(16_suppl). 11516–11516. 2 indexed citations
6.
Peyraud, Florent, Jean‐Philippe Guégan, Lucile Vanhersecke, et al.. (2023). Abstract 6767: Cancer-associated fibroblasts promote T-cell exclusion and resistance to immunotherapy in non-small cell lung cancer with tertiary lymphoid structures. Cancer Research. 83(7_Supplement). 6767–6767. 1 indexed citations
7.
Palmieri, Lola‐Jade, Sophie Cousin, Mariella Spalato Ceruso, et al.. (2023). Targeting EZH2 to overcome the resistance to immunotherapy in microsatellite stable colorectal cancer: Results from the CAIRE study.. Journal of Clinical Oncology. 41(16_suppl). 3599–3599. 2 indexed citations
8.
Bessede, Alban, Florent Peyraud, Sylvestre Le Moulec, et al.. (2023). Upregulation of Indoleamine 2,3-Dioxygenase 1 in Tumor Cells and Tertiary Lymphoid Structures is a Hallmark of Inflamed Non–Small Cell Lung Cancer. Clinical Cancer Research. 29(23). 4883–4893. 12 indexed citations
9.
Verbeke, Stéphanie, Jean‐Philippe Guégan, Laura Leroy, et al.. (2023). Antitumor Effects of PRMT5 Inhibition in Sarcomas. Cancer Research Communications. 3(11). 2211–2220. 1 indexed citations
10.
Italiano, Antoîne, Laura Leroy, Jean‐Philippe Guégan, et al.. (2023). TROP2 expression and response to immune checkpoint inhibition in patients with advanced non-small cell lung cancer.. Journal of Clinical Oncology. 41(16_suppl). 9040–9040. 2 indexed citations
11.
Bessede, Alban, Florent Peyraud, Benjamin Besse, et al.. (2023). TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research. 30(4). 779–785. 20 indexed citations
12.
Cousin, Sophie, Jean Philippe Metges, Carine Bellera, et al.. (2022). REGOMUNE: A phase II study of regorafenib plus avelumab in solid tumors—Results of the oesophageal or gastric carcinoma (OGC) cohort.. Journal of Clinical Oncology. 40(16_suppl). 4060–4060. 2 indexed citations
13.
Larroquette, Mathieu, Jean‐Philippe Guégan, Benjamin Besse, et al.. (2022). Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies. Journal for ImmunoTherapy of Cancer. 10(5). e003890–e003890. 105 indexed citations
14.
Bessede, Alban, Aurélien Marabelle, Jean‐Philippe Guégan, et al.. (2022). Impact of acetaminophen on the efficacy of immunotherapy in cancer patients. Annals of Oncology. 33(9). 909–915. 28 indexed citations
15.
Cousin, Sophie, Coralie Cantarel, Jean‐Philippe Guégan, et al.. (2021). Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial. Clinical Cancer Research. 27(8). 2139–2147. 95 indexed citations
16.
Qadir, Abdul S., Jean‐Philippe Guégan, Christophe Ginestier, et al.. (2021). CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells. iScience. 24(11). 103348–103348. 13 indexed citations
17.
Guégan, Jean‐Philippe, Christophe Ginestier, Emmanuelle Charafe‐Jauffret, et al.. (2019). CD95/Fas and metastatic disease: What does not kill you makes you stronger. Seminars in Cancer Biology. 60. 121–131. 33 indexed citations
18.
Nguyen, Ha Thanh, Jean‐Philippe Guégan, Amanda Poissonnier, et al.. (2019). Synthesis of peptidomimetics and chemo-biological tools for CD95/PLCγ1 interaction analysis. Bioorganic & Medicinal Chemistry Letters. 29(16). 2094–2099. 2 indexed citations
19.
Poissonnier, Amanda, Jean‐Philippe Guégan, Ha Thanh Nguyen, et al.. (2018). Disrupting the CD95–PLCγ1 interaction prevents Th17-driven inflammation. Nature Chemical Biology. 14(12). 1079–1089. 25 indexed citations
20.
Guégan, Jean‐Philippe, Frédéric Ezan, Luc Gailhouste, Sophie Langouët, & Georges Baffet. (2013). MEK1/2 Overactivation Can Promote Growth Arrest by Mediating ERK1/2-Dependent Phosphorylation of p70S6K. Journal of Cellular Physiology. 229(7). 903–915. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yurong Zhang Breakdown of academic impact, for papers by Arif Y. Shaikh Breakdown of academic impact, for papers by Yibing Bai Breakdown of academic impact, for papers by Lu Yue Breakdown of academic impact, for papers by Daya Luo Breakdown of academic impact, for papers by Carole Ferraro‐Peyret Breakdown of academic impact, for papers by Luyun He Breakdown of academic impact, for papers by Jen‐Yu Hung Breakdown of academic impact, for papers by Sara Baglivo Breakdown of academic impact, for papers by Rohit R. Jadhav
Rankless by CCL
2026